NAPLS Omega-3 Fatty Acid Versus Placebo Study
This study is ongoing, but not recruiting participants.
Sponsor:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT01429454
First Posted: September 7, 2011
Last Update Posted: December 2, 2015
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Kristin Cadenhead, M.D., University of California, San Diego
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The overall goal of the present study is to determine whether Omega-3 Fatty Acids potentially prevent onset of psychosis and improve clinical symptoms and functional outcome in youth and young adults at elevated clinical risk for schizophrenia and related disorders. The specific aims are: (1) To determine whether the rate of progression to psychosis is lower during six months of treatment with Omega-3 Fatty Acids compared to six months of treatment with placebo, (2) To determine whether Omega-3 Fatty Acids are more efficacious than placebo for prodromal symptoms, negative symptoms, and functioning, (3) To assess the safety and tolerability of Omega-3 Fatty Acids in this population, and (4) To conduct analyses of neuroimaging, neurocognitive, electrophysiological and other ancillary data to explore mechanistic explanations for the hypothesized benefits of Omega-3 Fatty Acids on clinical and functional outcomes (e.g., increases in white matter integrity and processing speed).
| Condition | Intervention | Phase |
|---|---|---|
| Psychosis | Drug: Omega-3 Long Chain Fatty Acid Drug: Placebo | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Randomized Double-Blind Trial of Omega 3 Fatty Acid Versus Placebo in Individuals at Risk for Psychosis |
Resource links provided by NLM:
Genetics Home Reference related topics:
schizophrenia
Drug Information available for:
Omega-3 Fatty Acids
U.S. FDA Resources
Further study details as provided by Kristin Cadenhead, M.D., University of California, San Diego:
Primary Outcome Measures:
- rate of conversion to psychosis [ Time Frame: 12 months ]The rate of conversion to psychosis among prodromal patients assigned at random to Omega-3 Fatty Acids at 12 months will be significantly lower than that among patients assigned to placebo.
Secondary Outcome Measures:
- Scale of Prodromal Symptoms (SOPS) total score (indexing severity of positive, negative, and general symptoms) [ Time Frame: 6 months and 12 months ]The reduction from baseline in the Scale of Prodromal Symptoms (SOPS) total score (indexing severity of positive, negative, and general symptoms) at 6 and 12 months will be significantly greater in prodromal patients assigned at random to Omega-3 Fatty Acids than in patients assigned to placebo.
| Estimated Enrollment: | 128 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | May 2016 |
| Estimated Primary Completion Date: | May 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Soybean-Corn Blend Capsule
The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
|
Drug: Placebo
The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
|
|
Experimental: Omega 3 long chain fatty acid
The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
|
Drug: Omega-3 Long Chain Fatty Acid
: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
Other Name: Fish Oil, Ocean Nutrition
|
Show Detailed Description
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 30 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects will be included if they are treatment-seeking patients between the ages of 12 and 30 who meet diagnostic criteria for a possible prodromal syndrome and are part of the ongoing NAPLS study.
Exclusion Criteria:
- use of antipsychotic medication in the previous month.
- concomitant medical or neurological illness.
- history of significant head injury.
- alcohol or drug abuse (excluding nicotine) in the past month or dependence in the past three months.
- screening full scale estimated IQ < 80.
- active suicidal or homicidal ideation.
- pregnancy or lactation.
- allergies to seafood or seafood related products or no history of seafood consumption
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01429454
Locations
| United States, California | |
| University of California, Los Angeles | |
| Los Angeles, California, United States, 90095 | |
| University of California, San Diego | |
| San Diego, California, United States, 92093 | |
| United States, Connecticut | |
| Yale University | |
| New Haven, Connecticut, United States, 06519 | |
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Massachusetts | |
| Harvard | |
| Boston, Massachusetts, United States, 02215 | |
| United States, New York | |
| Zucker Hillside Hospital | |
| Glen Oaks, New York, United States, 11004 | |
| United States, North Carolina | |
| University of North Carolina | |
| Chapel Hill, North Carolina, United States, 27599 | |
| United States, Pennsylvania | |
| VA Pittsburgh Healthcare System | |
| Pittsburgh, Pennsylvania, United States, 15206 | |
| Canada, Alberta | |
| University of Calgary | |
| Calgary, Alberta, Canada, T2N 1N4 | |
Sponsors and Collaborators
University of California, San Diego
National Institute of Mental Health (NIMH)
Investigators
| Principal Investigator: | Kristin S Cadenhead, MD | UCSD |
More Information
| Responsible Party: | Kristin Cadenhead, M.D., Principal Investigator, University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT01429454 History of Changes |
| Other Study ID Numbers: |
NAPLS- Omega3 U01MH081944 ( U.S. NIH Grant/Contract ) |
| First Submitted: | August 29, 2011 |
| First Posted: | September 7, 2011 |
| Last Update Posted: | December 2, 2015 |
| Last Verified: | November 2015 |
Keywords provided by Kristin Cadenhead, M.D., University of California, San Diego:
|
Prodromal Schizophrenia Psychosis Omega |
Additional relevant MeSH terms:
|
Psychotic Disorders Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders |